Bio-Techne (TECH) Other Non Operating Income (2009 - 2023)
Bio-Techne's quarterly Other Non Operating Income came in at -$3.5 million in Q2 2023, down 544.97% year-on-year from $796000.0 in Q2 2022, and down 1037.04% quarter-over-quarter from $378000.0 in Q1 2023.
Bio-Techne has reported Other Non Operating Income for 15 years, with the latest figure at -$3.5 million in Q2 2023.
- For the quarter ending Q2 2023, Other Non Operating Income fell 544.97% year-over-year to -$3.5 million; the trailing twelve-month figure through Jun 2023 stood at $47.5 million (up 210.35% YoY), and the FY2025 full-year result was $831000.0, up 109.68% from the prior year.
- Other Non Operating Income for Q2 2023 stood at -$3.5 million, down from $378000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $118.0 million in Q4 2019, with the low at -$58.3 million in Q2 2021.
- Average Other Non Operating Income over 5 years is $6.7 million, with a median of $587000.0 recorded in 2022.
- Peak annual rise in Other Non Operating Income reached 2005.59% in 2019, while the deepest fall reached 25355.0% in 2019.
- Tracing TECH's Other Non Operating Income over 5 years: stood at $118.0 million in 2019, then tumbled by 92.47% to $8.9 million in 2020, then soared by 198.29% to $26.5 million in 2021, then plunged by 100.28% to -$74000.0 in 2022, then plunged by 4686.49% to -$3.5 million in 2023.
- The last three Other Non Operating Income figures came in at -$3.5 million (Q2 2023), $378000.0 (Q1 2023), and -$74000.0 (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Bio-Techne | 7.92 Bn | 7.71 Bn | 208.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -3.54 Mn |
| Mar 31, 2023 | 378,000.00 |
| Dec 31, 2022 | -74,000.00 |
| Sep 30, 2022 | 50.76 Mn |
| Jun 30, 2022 | 796,000.00 |
| Mar 31, 2022 | -19.35 Mn |
| Dec 31, 2021 | 26.49 Mn |
| Sep 30, 2021 | 7.38 Mn |
| Jun 30, 2021 | -58.35 Mn |
| Mar 31, 2021 | -20.73 Mn |
| Dec 31, 2020 | 8.88 Mn |
| Sep 30, 2020 | -5.45 Mn |
| Jun 30, 2020 | 26.71 Mn |
| Mar 31, 2020 | 3.37 Mn |
| Dec 31, 2019 | 117.98 Mn |
| Sep 30, 2019 | -10.41 Mn |
| Jun 30, 2019 | -15.15 Mn |
| Mar 31, 2019 | 10.82 Mn |
| Dec 31, 2018 | -6.19 Mn |
| Sep 30, 2018 | -3.04 Mn |
| Jun 30, 2018 | 60,000.00 |
| Mar 31, 2018 | 542,000.00 |
| Dec 31, 2017 | -154,000.00 |
| Sep 30, 2017 | -897,000.00 |
| Jun 30, 2017 | -360,000.00 |
| Mar 31, 2017 | -326,000.00 |
| Dec 31, 2016 | -861,000.00 |
| Sep 30, 2016 | -20,000.00 |
| Jun 30, 2016 | -1.87 Mn |
| Mar 31, 2016 | -654,000.00 |
| Dec 31, 2015 | -302,000.00 |
| Sep 30, 2015 | 1.21 Mn |
| Jun 30, 2015 | 9.00 Mn |
| Mar 31, 2015 | -411,000.00 |
| Dec 31, 2014 | -51,000.00 |
| Sep 30, 2014 | -492,000.00 |
| Jun 30, 2014 | -438,000.00 |
| Mar 31, 2014 | -229,000.00 |
| Dec 31, 2013 | -71,000.00 |
| Sep 30, 2013 | -304,000.00 |
| Jun 30, 2013 | 278,000.00 |
| Mar 31, 2013 | -118,000.00 |
| Dec 31, 2012 | -135,000.00 |
| Sep 30, 2012 | -478,000.00 |
| Jun 30, 2012 | -1.24 Mn |
| Mar 31, 2012 | -373,000.00 |
| Dec 31, 2011 | -607,000.00 |
| Sep 30, 2011 | -1.18 Mn |
| Jun 30, 2011 | -450,000.00 |
| Mar 31, 2011 | -421,000.00 |
| Dec 31, 2010 | -698,000.00 |
| Sep 30, 2010 | -257,000.00 |
| Jun 30, 2010 | -1.34 Mn |
| Mar 31, 2010 | -1.25 Mn |
| Dec 31, 2009 | -1.01 Mn |
| Sep 30, 2009 | -662,000.00 |